Impact of porous microsponges in minimizing myotoxic side effects of simvastatin

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Toxicology

Background:

• Simvastatin (SV) is a poorly soluble drug with oral administration challenges.
• Myopathy is a significant adverse effect associated with oral simvastatin.
• Developing novel drug delivery systems can mitigate SV-induced toxicity.

Purpose of the Study:

• To formulate simvastatin (SV) microsponges.
• To evaluate the potential of SV microsponges in minimizing oral administration-associated myotoxicity.
• To assess the safety and efficacy of SV microsponges compared to free SV.

Main Methods:

• SV microsponges were prepared using the emulsion solvent evaporation technique.
• Characterization included entrapment efficiency, particle size, cumulative drug release, and specific surface area.
• In vivo studies involved histological, glycogen histochemical, and gene expression analyses (Mfn1, Fis1, PGC-1α) in rat skeletal muscles.

Main Results:

• High entrapment efficiency (~82.54%) and controlled particle size (53.80–86.03 µm) were achieved.
• SV microsponges exhibited significantly higher cumulative drug release compared to free SV dispersion.
• Histological and gene expression studies confirmed reduced myotoxicity with SV microsponges versus free SV.

Conclusions:

• SV microsponges demonstrate a significant reduction in myotoxicity compared to free simvastatin.
• The developed microsponges offer a promising approach for safer oral administration of simvastatin.
• This formulation has the potential to improve patient outcomes by mitigating SV-induced muscle damage.